Basics 2 Flashcards
(96 cards)
Drug discovery
Disease target, molecular design/screening, congeners/me too drugs.
Must be tested in animal and human trials, chronic toxicity not usually required
Drug discovery is very expensive and time consuming.
Animal testing: General screening tests for:
pharmacological effects hepatic/renal functioning blood/urine tests gross and histopathologic exams reproductive effects toxicity
What is acute toxicity?
Admin of a single dose of the agent up to lethal dose i at least 2 species. usually 1 rodent and 1 non-rodent
sub ac
What is sub acute toxicity?
2-4 weeks, at least 2 species
What is chronic toxicity?
6-24 mos, at least 2 species
Repro toxicity: what is teratogenic?
Effect on the In Utero Development of an organism resulting in abnormal structure or function-generally not heritable.
Repro toxicity: what is mutagenic?
Effect on the inheritable characteristics of a cell or organism-mutation in DNA.
What is AMES test?A
Standard IN VITRO test for mutagenicity-used for toxicity!
Uses salmonella bacteria, and also used in carcinogenesis test.
What is Dominant Lethal Test?
IN VIVO! test for toxicity. Males are exposedto substance and abnormalities looked for in progeny
FDA approval: Investigational New Drug (IND)
requires animal data, application for FDA approval to carry out new drug trials in humans
FDA approval:New Drug Application (NDA)
Application for FDA approval to market a new drug for ordinary clinical use-requires data from clinical trials as well as animal data.
Clinical Trials: phase I
studies safety of medication and treatment.
20-80 participants
up to several months
Clinical Trials: phase II
Studies the efficacy.
100-300 participants
up to 2 years
Clinical Trials: phase III
Studies safety, efficacy, and dosing.
1-3K participants
1-4 years
Clinical Trials: phase IV
Studies the long-term effectiveness; cost effectiveness.
Thousands of participants
1 yr+
Drug patents:
patent applications usually submitted during animal testing, 20 yrs non competition allowance.
After 20 yrs, generics are allowed into the market, but prove BIOEQUIVALENCE
Orphan Drugs?
Used for rare diseases. Uncommon in R&D b/c cost may not outweigh profit-> may be some federal incentives like grants etc.
Schedule I
No currently accepted medical use in the US. a lack of accepted safety for use under medical supervision, and a HIGH POTENTIAL FOR ABUSE. i.e. heroin, LSD, marajuana,peyote, ecstasy etc
Schedule II
High potential for abuse, may lead to severe psychological or physical dependence. ie codeine, amphetamine, phenobarbitol
Schedule III
Less potential for abuse-moderate to low physical dependence or high psychological dependence. hydrocodone anabolic steroids
Schedule IV
Low potential for abuse relative to schedule III. ie ativan, alprazolam
Schedule V
Low potential for abuse, relative to schedule IV and consists primarily of preparations containing limited qtys of certain narcotics. i.e. cough meds containing no more than 200mg codeine per 100 mL= robitussin
What is an analog?
Drug whose structure is related to another drug. i.e. extra hydrogen, hydroxyl, or methyl group.
Chemical and biological properties may be quite different.
“similar” drugs with similar properties
What is a congener?
substance synthesized by essentially the same synthetic chemical runs and the same procedures as another drug. ie tires. . . .
Congeners and analogs placed into same schedule . ..”designer drugs”